Genentech Inc, a US biotechnology research company, plans to found a research joint venture with the Taiwanese government in Hsinchu to develop AIDS treatments headed by Taiwanese-American researcher David Ho (何大一), Chinese-language news-papers said yesterday.
Ho has reportedly agreed to serve as chairman of the planned joint-venture -- to be known as TaiMed -- which is to be set up in Hsinchu Biochemical Science Park (新竹生醫科學園區), reports quoted Liang Chi-ming (梁啟銘), director of the Office of Public Affairs at the Academia Sinica, as saying.
Academia Sinica is the nation's top research institute.
South San Francisco-based Genentech will transfer its CD4 antibody technology to TaiMed, the United Daily News said, citing Liang.
CD4, which exists on the membrane of T cells, is a primary receptor used by HIV-1 to gain entry into host T cells, which plays an essential role in cell-mediated immunity and targets of HIV infection. If developed successfully, the CD4 antibody will block CD4 from destroying the immune system.
Funding for the joint-venture should reach NT$3 billion (US$90.5 million) for the first three years, with the Cabinet's Development Fund investing in as much as 45 percent of that, the paper quoted Liang as saying. The rest of the funds will come from private enterprises and venture capital, the paper said.
The China Times carried a similar report yesterday, citing Council for Economic Planning and Development chairwoman Ho Mei-yueh (
But the government investment will not exceed 45 percent, or the company would become state-run, Ho said in the report.
Liang said that the project was initiated by Academia Sinica President Wong Chi-huey (翁啟惠), who hopes to establish a research firm to attract overseas Taiwanese biotech researchers back to the nation.
Ho, well-known for pioneering the use of protease inhibitors in treating HIV-infected patients with his team, will be hired as a researcher by the Academia Sinica and then assume the chairmanship of TaiMed, the reports said, quoting Liang.
The CD4 treatment, along with Ho's cocktail drug for curbing AIDS in its early period, will be the focus at TaiMed, Liang said.
If the new drug is successful, TaiMed could earn royalties from drug manufacturers and obtain sales right in East Asia, he said.
The legislature passed the Biotech and New Pharmaceutical Development Act (生技新藥產業發展條例) last Friday, which allows government researchers to transfer their knowledge to private companies developing new drugs.
Units of Intel Corp and Samsung Electronics Co are targeting to resume full operations of their Ho Chi Minh City plants by the end of next month, a move that could provide relief to global supply chains. Saigon Hi-Tech Park is helping its tenants, many of which are running at about 70 percent capacity, to operate fully next month, park deputy manager Le Bich Loan said in a phone interview. She did not elaborate on the steps the park is taking, particularly efforts at bringing back workers who fled to home provinces. The Ho Chi Minh City unit of Nidec Sankyo Corp,
CHIP CRUNCH: Apple’s woes show that even the king of the technology world is not immune from global shortages made worse by the COVID-19 pandemic Apple Inc is likely to slash its projected iPhone 13 production targets for this year by as many as 10 million units as prolonged chip shortages hit its flagship product, people with knowledge of the matter said. The company had expected to produce 90 million new iPhone models in the final three months of this year, but it is now telling manufacturing partners that the total would be lower because Broadcom Inc and Texas Instruments Inc are struggling to deliver enough components, the people said. Apple gets display parts from Texas Instruments, while Broadcom is its longtime supplier of wireless components. One Texas
EVA Airways Corp (長榮航空) and China Airlines Ltd (中華航空), the nation’s two major airlines, reported accelerated revenue growth in the third quarter compared with the previous two quarters, thanks to robust air cargo business. EVA Airways yesterday said sales for last quarter rose 40 percent year-on-year to NT$25.81 billion (US$917 million), compared with an increase of 25 percent in the second quarter and a fall of 35 percent in the first quarter. China Airlines said sales grew 39 percent to NT$34.6 billion in the third quarter, after gaining 10 percent in the second quarter and falling 14 percent in the first quarter. EVA
Hon Hai Precision Industry Co (鴻海精密) is embarking on a recruitment drive to hire 200,000 workers in Shenzhen, China, as it ramps up production of the new iPhone 13 series, Chinese business news outlet Eastmoney.com reported. Hon Hai is seeking to recruit those heading back to the city after China’s seven-day National Day holiday, which began on Oct. 1, to help churn out the estimated 100,000 iPhone 13s produced on the site each day, the report said. Following last month’s global release of the iPhone 13, Hon Hai entered its traditional peak season, and workers at its Chinese production sites are said